晨间信号Morning Signal
《今日营养师》 第28卷 第3期 · 2026年5月刊 · 中文解读

GLP-1受体激动剂全面解析:为医疗保健专业人员提供的最新指南

CPE Monthly: Understanding GLP-1 Receptor Agonists · Alexandria Hardy, RDN, LDN
约 41 分钟Departments在小程序里点播,20 到 60 分钟做好
这篇讲什么
本文为医疗保健专业人员提供关于GLP-1受体激动剂的全面概述,涵盖其作用机制、临床疗效、副作用管理及营养支持策略。
原文开头
CPE Monthly By Alexandria Hardy, RDN, LDN Understanding GLP-1 Receptor Agonists A Comprehensive Overview for Health Care Professionals T he rising prevalence of obesity and diabetes has led to booming interest in treatments such as glucagonlike peptide-1 recep- tor agonists (GLP-1 RA or GLP-1) medica- tions. GLP-1s have demonstrable efficacy in weight management and glycemic con- trol, making them a key tool for clinicians addressing these conditions. In 2023, semaglutide was the best-selling drug in the United States with nearly $14 billion in sales.1 There are an estimated 100 million obese adults in America, and an addi- tional 37 million who may also be eligible to use medications like GLP-1s to man- age chronic conditions. …
摘自《今日营养师》(Today's Dietitian)第28卷 第3期 · 2026年5月刊,Alexandria Hardy, RDN, LDN。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。
晨间信号小程序码
微信扫码,在小程序里听完整版
不用登录先听一篇 · 或在微信搜索小程序 晨间信号
同期其他文章